Latest The Hydration Pharmaceuticals Company (Asx:Hpc) News

Page 1 of 1
Hydralyte USA reported a 6% year-on-year sales increase in Q3 FY25 alongside a significant 42% reduction in operating cash burn, driven by a streamlined US-focused model and new product launches in brain and gut health.
Ada Torres
Ada Torres
31 Oct 2025
Hydralyte USA reports an 11% sales increase in Q3 2025, driven by strong summer demand and the launch of its innovative Hydralyte Plus Brain Support product featuring nootropics.
Victor Sage
Victor Sage
3 Oct 2025
The Hydration Pharmaceuticals Company Limited reported a 55% reduction in half-year losses to $1.44 million, driven by strategic cost reductions and a sharpened focus on US e-commerce operations. Despite a 15% revenue decline, the company is banking on new product launches and retail expansion to fuel growth.
Ada Torres
Ada Torres
29 Aug 2025
Hydralyte USA reported an 8.5% rise in Q2 FY25 net sales, driven by strong May performance and improved margins, while preparing to launch new brain and gut health products.
Ada Torres
Ada Torres
31 July 2025
Hydralyte USA has completed its Rights Issue by placing 5 million shortfall shares, raising a total of $608,878 before costs. The move finalizes the company’s recent capital raising efforts under full regulatory compliance.
Ada Torres
Ada Torres
10 July 2025
Hydralyte USA has placed 39.5 million shortfall shares at $0.01 each, boosting total funds raised under its recent Rights Issue to nearly $559,000. The move strengthens the company’s capital position amid ongoing growth efforts.
Victor Sage
Victor Sage
8 July 2025
Hydralyte USA reported its strongest monthly sales in May 2025, alongside continued improvement in EBITDA losses, signaling steady progress toward profitability.
Ada Torres
Ada Torres
19 June 2025
Hydralyte USA reports its best EBITDA performance since IPO, driven by strong sales and cost reductions, setting the stage for growth with upcoming product launches.
Ada Torres
Ada Torres
2 June 2025
Hydralyte North America reported a 16% rise in Q1 FY25 net sales and improved gross margins, supported by a strategic capital raise and upcoming product launches targeting brain and gut health.
Ada Torres
Ada Torres
30 Apr 2025
HydraLyte USA has completed the divestiture of its non-US assets, wiping out debt and boosting cash reserves to US$3.2 million, while focusing its growth strategy on the US ecommerce market with a 28% quarterly revenue increase.
Ada Torres
Ada Torres
31 Jan 2025